

POSTERS LIST

MDR-1 and CYP3A5 Polymorphisms in Pediatric Idiopathic Nephrotic Syndrome: Impact on Susceptibility and Response to Steroids (Preliminary Results)	Amira Moussa Ep Chaouache	1
A pharmacogenetic study for clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy	Annamaria Ruzzo	2
A time-dependent model describes methotrexate elimination and supports dynamic modification of MRP2/ABCC2 activity.	Chantal Barin Le Guellec	3
Single nucleotide polymorphisms of ABCC2 modulate renal secretion of endogenous organic anions.	Chantal Barin Le Guellec	4
INTEGRATED IN-SILICO, IN-VIVO AND CLINICAL APPROACH FOR IDENTIFICATION OF MIRNAS AS BIOMARKERS AND PHARMACOLOGICAL TARGETS FOR RETINAL DEGENERATIVE DISEASES	Chiara B. M. Platania	5
P.T790M positive patients with advanced NSCLC resistant to first-line EGFR-tyrosine kinase inhibitors may display a low ratio of resistance vs. activating EGFR mutations	Eleonora Rofi	6
Comparison of Four Different Assay Methods for UGT1A1*28 Genotyping	Filomena Costanza	7
Two years of DPD pre-therapeutic screening: feedback of routine laboratory	Vanna Geromel	8
Implementation of pharmacogenetics in a hospital of the Spanish National Health System	Irene Garcia Garcia	9
The role of pharmacogenetics in rediscovering old drugs – spotlight on amitriptyline	Luana Mifsud Buhagiar	10
How many of them could be avoided? The importance of implementing pharmacogenetics into clinical practice	Lucia Gozzo	11
Prioritizing Individuals and Patient Populations for Clinical Pharmacogenomics Testing	Hachad Honda	12
Effects of CYP3A5 and ABCB1 polymorphism of donors and recipients over chronic nephropathy in adult recipients of liver transplant treated with tacrolimus: cohort study	Luis Rojas	13
Pharmacogenetics of Chemotherapy in Pediatric Oncology: variant frequencies different from those expected in Caucasian children with Neuroblastoma.	Maria Jose Herrero	
Association of the SLCO1B1*15 Haplotype with myopathies under statins	Marwa Ajmi	14
Influence of genetic and non-genetic factors on Acenocoumarol maintenance dose requirement in a Tunisian population	Marwa Ajmi	15
Establishing multi-lingual, multi-modal pharmacogenomic decision support across seven European countries	Matthias Samwald	16
Association Of CYP2C19 Gene rs4986893 Polymorphism With Clinical Cardiovascular Events In Patients Using Clopidogrel	Mehtap Cevik	17
Genetic Polymorphisms of CYP3A4*1B In Patients With Coronary Artery Disease Using Statin	Mehtap Cevik	18
Association of Cyp2C19 gene rs4244285 polymorphism with Clinical Cardiovascular events in patients using Clopidogrel	Mehtap Cevik	19

Investigation of CYP2C9*2 Polymorphism In Patients With Cardiovascular Disease Using Warfarin	Mehtap Cevik	20
Vascular endothelial growth factor and its type 1 and 2 receptors in blood serum of renal cancer patients: clinical and pathologic correlations	Nikolay Kushlinskii	21
RANK/RANKL/OPG ligand/receptor system components and inflammatory cytokines in blood serum of primary bone tumor patients: association with clinical and pathological characteristics and potential clinical implication	Nikolay Kushlinskii	23
Pharmacogenomic biomarker information in drug labels in Hungary: ready for personalized medicine?	Réka Várnai	24
Single tube CYP2D6 Copy number analysis for multiple regions in the gene	Robin Everts	25
EVALUATION OF PLASMA CELL-FREE DNA (CFDNA) ISOLATION METHODS IN BREAST CANCER	Sandra Supraha Goreta	26
Pharmacogenetic and pharmacovigilance data recording system in pain therapy	Peiro Ana	27
Pharmacogenomics for optimizing pain therapy		
Pharmacological inhibition of histone acetyltransferase reduces endothelin-1 expression and mitigates markers of vascular dysfunction in diabetes	Simona-Adriana Manea	29
Allele and Genotype Frequencies of CYP2B6 Gene *9 Polymorphism in a Turkish Population	Sinan Suzen	30
Serotonin Transporter Gene Promoter Variation and Response to Citalopram in Depressed Patients	Sinan Suzen	31
Detection of AR-V7 in plasma-derived exosomal RNA in metastatic prostate cancer patients treated with first-line hormonal therapy	Stefania Crucitta	32
NUDT15: A GREAT LEAP FORWARD IN MANAGING THIOPURINE INDUCED TOXICITY	Swarup Shah	33
Genetic polymorphism of CYP2C19 and CYP2D6 in a large French psychiatric population: frequencies and case report illustration	Sylvie Quaranta	34
Toxic-death case after capecitabine (Xeloda®) intake: pharmacogenetic investigations	Sylvie Quaranta	35
TPMT polymorphisms and 6-TGN levels upon azathioprine therapy in pediatric patients with inflammatory bowel disease	Sylvie Quaranta	36
Pharmacogenetics-based personalized therapy: levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPgX) regarding 4 major therapeutic domains.	Sylvie Quaranta	37
ARTE – Ecosystem for advanced therapies in regenerative medicine	Tilen Kranjc	38
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 update	Ursula Amstutz	39
Genome-wide association study (GWAS) of central pain sensitization in fibromyalgia patients	Yvonne Gloor	40
Novel hypermethylated miRNA genes in ovarian carcinoma pathogenesis and metastasis	Nikolay Kushlinskii	41
Pharmacogenetic prediction of metoprolol effectiveness in turkish patients with coronary artery disease	Belgin Ssleyici	42
Cost-evaluation of fluoropyrimidines-related toxicities based on patients genotype according to a DPYD four-SNPs	Rossana Roncato	43
Identification of putative substrates and inhibitors for Glutathione S-transferases using computational methods	Chakradhara Rao S Uppugunduri	44
Influence of TPMT and MTHFR genotypes on maternal and fetal markers of oxidative stress and pregnancy outcomes - a pilot study	Alenka Smid	45

Discontinuation and Dose Adjustments of Metoprolol after Paroxetine/Fluoxetine-Metoprolol Co-prescriptions in Dutch Elderly	Muhammad Akbar Bahar	46/47
Characterization of the transcriptional changes induced by Eltrombopag treatment in chronic immune thrombocytopenia patients	Bastida, Hernández-Sánchez, Alonso-López, Lumbreras Eva, Bueno Rebeca, Hernández-Rivas, González-Porras, Rodríguez Ana	48
The potential contribution of SNP-SNP interactions within the DNA mismatch repair pathway to thyroid cancer susceptibility	Luis Santos	49
THE POTENTIAL IMPACT OF DNA REPAIR SNPS ON DNA DAMAGE LEVELS OF LYMPHOCYTES FROM 131-TREATED THYROID CANCER PATIENTS	Luis Santos	50
The Effects of Clopidogrel on DNA damage in Adipocyte and Hepocyte Cell Lines	Elif Bayar	51
Automated requisition of pharmacogenetic testing	Claus Brasen	52
Comparison of Biorad ddPCR, Roche Cobas Z480 and Autogenomics INFINITY for detection of EGFR T790M mutation in plasma cell free DNA of lung cancer patients	E. De Jonge, N. van den Donk, S. Callistri, R. de Clerq, M. del Re, R.H.N. van Schaik	53
Association of NR1/2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity	Litaty Mbatchi	54
Genetic variations of the xenoreceptors NR1/2 (PXR) and NR1/3 (CAR) and their effect on the variability of drug disposition and response	Litaty Mbatchi	55
Genetic variations and nephrotoxicity of cisplatin: a systematic review	Zulfan Zazuli	56
Alteration of DNA-methylation in tyrosine kinase inhibitor resistant CML K-562 cells	Johanna Ruemenapp	57
Insights into imatinib-resistance - miR-212/ABCG2-axis contributes to development of drug resistance in chronic myeloid leukemia	Meike Kaehler	58
Regulation of clinically relevant multidrug transporters by different microRNAs along the human intestine	Henrike Bruckmüller	59
Creation of a maternal/neonatal biobank to study the effects of maternal nutrition during pregnancy on fetal epigenome	Silvia Motta	60
MassARRAY-based simultaneous detection of hotspot somatic mutations and recurrent fusion genes in papillary thyroid carcinoma: the PTC-MA assay	Chiara Pesenti	61
THE ROLE OF GENETIC POLYMORPHISMS OF METABOLIZING ENZYMES, TRANSPORTERS AND RECEPTORS ON PHARMACOKINETICS AND SAFETY OF SERTRALINE IN HEALTHY SUBJECTS	Miriam Saiz-Rodríguez	62
Effects of aripiprazole and dehydro-aripiprazole on pupillometry parameters related to pharmacokinetics and pharmacogenetics in healthy subjects	Dora Koller	63
Microbiota and genetic profile for personalizing therapy in a multiple sclerosis patient	Federica Valeriani, Vincenzo Romano Spica	64
Changes in serum levels of kynurenine metabolites in paediatric patients affected by attention deficit hyperactivity disorder adhd	Ottavia De Luca	65
A nomogram combining genomic and phenotypic data to predict 5-fluorouracil toxicity	Marina Borro	66

Genetic association analysis of serotonin and signal transduction pathways in suicide attempters from an Italian sample of psychiatric patients	Laura Aimati	67
Variants in <i>IL17A</i> are associated with asthma control in a South American Population	Milca de J. Silva, Maria B. R. Santana, Neuza Maria Alcântara-Neves, Mauricio L. Barreto, Álvaro Augusto Cruz Filho, Camila Alexandrina Figueiredo, Ryan Santos Costa	68
Impact of CYP3A5/CYP2C19 Pharmacogenetics on Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation Using Tacrolimus and Sirolimus as GVHD Prophylaxis	Samer K. Khaled	69
Identification of Novel Genetic Variant on N-Acetyltransferase 2 Gene (NAT2) with In Silico Functionality among Jordanian Population	Yazun Bashir Jarrar, Ayat Ahmed Balasmeh and Wassan Jarrar	70
Omiterc Project: application of OMICS from solid to liquid biopsy for the personalized therapy of cancer	Marina Ziche	71